Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of BH259 for injection in advanced solid tumors
CTR20251856Phase 2Active
- Sponsor
- Zhuhai Beihai Biotech
- Start
- May 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of BH259 in Nonhematologic neoplasms, sponsored by Zhuhai Beihai Biotech. Started May 2025; status: active.
02
Drugs
BH259
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20251856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251856.